Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses Meeting Abstract

cited authors

  • Halmos, Balazs, Pennell, Nathan A., Otterson, Gregory Alan, Gadgeel, Shirish M., Mekhail, Tarek, Snell, Michael Robert, Kuebler, J. Phillip, Fu, Pingfu, Sharma, Neelesh, Dowlati, Afshin

authors

Publication Date

  • May 20, 2013

webpage

published in

category

volume

  • 31

issue

  • 15

WoS Citations

  • 0

WoS References

  • 0